SEC Form 4 · accession 0001179110-18-002113
MOMENTA PHARMACEUTICALS INC · MNTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Craig A Wheeler
Officer — President & CEO · Director
Period of report
Feb 12, 2018
Accepted (ET)
Feb 14, 2018 · 6:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235010
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 12, 2018 | S | 1,773 | $16.18 | D | 258,713 | D | |
| Common StockF4 | Feb 14, 2018 | S | 16,875 | $16.14 | D | 241,838 | D | |
| Common Stock | holding | — | — | — | 329,324 | I | Craig Wheeler Revocable Trust | |
| Common Stock | holding | — | — | — | 45,980 | I | Craig A Wheeler 2016 Annuity Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF5,F6 | — | Feb 12, 2018 | A | 98,750 | A | — | — | Common Stock | 98,750 | 98,750 | D |
| Stock Option (Right to Buy)F7 | $16.30 | Feb 12, 2018 | A | 197,500 | A | — | Feb 12, 2028 | Common Stock | 197,500 | 197,500 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person June 13, 2016.
- F2This transaction was executed in multiple trades at prices ranging from $16.05 to $16.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F3This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 1, 2016.
- F4This transaction was executed in multiple trades at prices ranging from $15.15 to $16.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F5Each Restricted Stock Unit represents a contingent right to receive one share of MNTA common stock.
- F6Subject to certain criteria, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years.
- F7Subject to certain criteria, the stock options will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years.